When employing a three-fold higher cut-off (as suggested by the manufacturer), diagnostic performance of the anti-CCP3.1 assay became comparable to the anti-CCP2 assay since 24 disease controls (but only 6 early RA patients) became negative. Here, AGBL2 is linked to rheumatoid arthritis.